patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
inhaled interferon - versus potential COVID-19 treatments - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 2.45 [0.21, 28.37]< 1 0% 2 studies (2/-) 23.8 % some concern not evaluable moderate crucial - deaths 0.80 [0.41, 1.58]< 1 0% 5 studies (5/-) 73.7 % NA not evaluable crucial - clinical deterioration 0.65 [0.42, 1.00]< 1 0% 3 studies (3/-) 97.6 % NA not evaluable important - clinical improvement 1.64 [0.98, 2.76]> 1 33% 3 studies (3/-) 96.9 % some concern not evaluable moderate important - clinical improvement (14-day) 2.11 [0.60, 7.41]> 1 65% 3 studies (3/-) 87.8 % some concern not evaluable moderate important - clinical improvement (28-day) 3.42 [1.70, 6.88]> 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate important - clinical improvement (7-day) 1.90 [1.07, 3.35]> 1 0% 2 studies (2/-) 98.6 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.29 [0.76, 2.18]> 1 76% 2 studies (2/-) 82.5 % low not evaluable high important - death or ventilation 0.75 [0.42, 1.34]< 1 0% 2 studies (2/-) 83.7 % NA not evaluable important - hospital discharge 1.07 [0.90, 1.28]> 1 0% 2 studies (2/-) 79.0 % NA not evaluable important - mechanical ventilation 0.52 [0.02, 15.78]< 1 0% 1 study (1/-) 64.5 % NA not evaluable important - Recovery (time to event analysis only) 1.02 [0.81, 1.28]> 1 0% 1 study (1/-) 56.7 % NA not evaluable important - viral clearance 2.90 [1.64, 5.14]> 1 0% 3 studies (3/-) 100.0 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 1.74 [1.10, 2.75]> 1 0% 1 study (1/-) 99.1 % NA not evaluable important - viral clearance by day 14 0.38 [0.00, 46.74]> 1 98% 3 studies (3/-) 35.1 % some concern not evaluable moderate important - viral clearance by day 7 2.52 [1.55, 4.09]> 1 0% 3 studies (3/-) 100.0 % some concern not evaluable moderate important - recovery 2.19 [1.03, 4.67]> 1 0% 1 study (1/-) 97.9 % NA not evaluable non important - 00 serious adverse events 0.95 [0.02, 50.33]< 1 0% 1 study (1/-) 51.0 % NA not evaluable important - adverse events 1.68 [0.47, 5.97]< 1 0% 1 study (1/-) 21.1 % NA not evaluable non important -
LoD: level of statistical demonstration:
